Gilead Buys Out Rights to Cancer Therapy From Jounce for $67 Million

Gilead Sciences will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics for $67 million, the drugmaker said on Tuesday.
Reuters Health Information